AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9305226
Drug: Antihistamine-treated group
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine-treated group
Trial: 9305226
Drug: Immunotherapy group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy group
Trial: 29307660
Drug: Paricalcitol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paricalcitol (2 μg/day for 12 weeks)
Trial: 29092731
Drug: Single CER
RxNorm normalized name: CER-001
DrugBank: CER-001 (DB18538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single CER intact capsule (30 mg)
Trial: 29092731
Drug: Single CER
RxNorm normalized name: CER-001
DrugBank: CER-001 (DB18538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single CER capsule contents sprinkled over applesauce (15 mL)
Trial: 24136051
Drug: Zero-profile implant
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zero-profile implant
Trial: 19100931
Drug: Rocuronium (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium (0.3 mg kg(‐1) IV)
Trial: 19100931
Drug: Succinylcholine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (1 mg kg(‐1) IV)
Trial: 16785771
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy (PCT)
Trial: 20621334
Drug: Cognitive‐behavior therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavior therapy (CBT)
Trial: 12695418
Drug: NG‐monomethyl‐L‐arginine (nitric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG‐monomethyl‐L‐arginine (nitric oxide synthase inhibitor)
Trial: 1514723
Drug: Nebulized magnesium
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized magnesium sulfate (3 mL, 268 mmol/L, pH 6.4)
Trial: 1514723
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol (2.5 mg in 3 mL saline)
Trial: 1514723
Drug: Nebulized normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized normal saline (3 mL)
Trial: 26720847
Drug: 70 IU/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 IU/kg intravenous unfractionated heparin (UFH) bolus
Trial: 11865170
Drug: Prednisolone 10
RxNorm normalized name: prednisolone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 10 mg tid
Trial: 11865170
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (less severe hyperemesis, no steroid therapy)
Trial: 10199874
Drug: L-arginine (6.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (6.7 g/min for 45 minutes)
Trial: 10199874
Drug: DIP (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIP (intravenous dipyridamole)
Trial: 8786246
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (150 mg twice daily) - Neoral
Trial: 8786246
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (150 mg twice daily) - Sandimmune
Trial: 6996935
Drug: guanabenz (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guanabenz (mean dose 24 mg daily)
Trial: 31419023
Drug: Structured ostomy
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured ostomy care training (oral and practical training, question and answer session, and an ostomy information booklet)
Trial: 12750665
Drug: 1-phase treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-phase treatment with bionator
Trial: 19577150
Drug: 2-phase treatment
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-phase treatment with headgear/biteplane
Trial: 18046226
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of high-dose triamcinolone acetonide (20-25 mg)
Trial: 18046226
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of dexamethasone (500 mug)
Trial: 15501952
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2 i.v. day 1) and capecitabine (1000 mg/m2 orally twice daily days 2‐15) for four cycles (Dose A)
Trial: 15501952
Drug: Docetaxel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (60 mg/m2 i.v. day 1) and capecitabine (937.5 mg/m2 orally twice daily days 2‐15) for four cycles (Dose B)
Trial: 11384089
Drug: Capecitabine as
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine as first-line treatment for metastatic breast cancer
Trial: 11384089
Drug: Low-dose CMF
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CMF (control group)
Trial: 9021428
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (450 mg propafenone)
Trial: 9021428
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (600 mg propafenone)
Trial: 3148366
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered thyrotropin-releasing hormone (TRH) (40 mg/day for 10 days)
Trial: 29685026
Drug: Biophysical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biophysical therapy using a Med Select 729 device
Trial: 29685026
Drug: Ibuprofen (non-steroidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (non-steroidal anti-inflammatory drug)
Trial: 25234648
Drug: Elosulfase alfa
RxNorm normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Elosulfase alfa at 2.0 mg/kg administered weekly for 24 weeks
Trial: 25234648
Drug: Elosulfase alfa
RxNorm normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Elosulfase alfa at 2.0 mg/kg administered every other week for 24 weeks
Trial: 25234648
Drug: Weekly dosing
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly dosing cohort
Trial: 25234648
Drug: Both dosing
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosing cohorts
Trial: 23261008
Drug: PSYMEPHY (interdisciplinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSYMEPHY (interdisciplinary treatment, 12 sessions)
Trial: 23261008
Drug: Standard pharmacologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmacologic therapy (control group)
Trial: 18690162
Drug: tesamorelin 2
RxNorm normalized name: tesamorelin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tesamorelin 2 mg
Trial: 10746426
Drug: Alendronate 35
RxNorm normalized name: ALENDRONATE 35MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 35 mg twice-weekly
Trial: 10746426
Drug: Once-weekly dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly dosing group
Trial: 8636828
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (1500 micrograms of beclomethasone via spacer for 30 days)
Trial: 8636828
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without inhaled corticosteroids
Trial: 4054524
Drug: Polycose meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polycose meal volume of 300 ml
Trial: 4054524
Drug: Polycose meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polycose meal energy density of 0.7 kcal/ml
Trial: 31895638
Drug: Unpreserved 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unpreserved 0.9% saline solution (Hydrabak®) eye drops
Trial: 29976109
Drug: Theoretical narrative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theoretical narrative medicine education for 1 term (Group 2)
Trial: 29976109
Drug: Narrative medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative medicine education integrating theory with practice for 2 terms (Group 3)
Trial: 27515419
Drug: cilnidipine (N/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilnidipine (N/L type CCB)
Trial: 27515419
Drug: amlodipine (L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine (L type CCB)
Trial: 24573731
Drug: L-menthol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-menthol (20 mL of 1.6% L-menthol)
Trial: 15829018
Drug: Zafirlukast (leucotriene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zafirlukast (leucotriene antagonist) for four weeks, along with doxycycline
Trial: 12005317
Drug: Methylphenidate (5
RxNorm normalized name: methylphenidate (50/50 release) 20 mg/24 hr oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (5 to 15 mg)
Trial: 11199824
Drug: Pulsed Nd:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Nd:YAG laser treatment at cervical regions with black ink
Trial: 11199824
Drug: Pulsed Nd:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Nd:YAG laser treatment at cervical regions without black ink
Trial: 11199824
Drug: Pulsed Nd:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Nd:YAG laser treatment at apical regions with black ink
Trial: 11199824
Drug: Pulsed Nd:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Nd:YAG laser treatment at apical regions without black ink
Trial: 8705220
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of norfloxacin twice daily for one week
Trial: 8705220
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of norfloxacin twice daily for one day
Trial: 8705220
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of norfloxacin twice daily for one week (in patients with risk factors)
Trial: 8705220
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of norfloxacin twice daily for one day (in patients with risk factors)
Trial: 1846868
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRH-a) alone
Trial: 12579102
Drug: Diltiazem (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (180 mg)
Trial: 1755948
Drug: Nifedipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (30 mg)
Trial: 9404431
Drug: Antihypertensive treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatments
Trial: 24696507
Drug: PF‐04494700 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐04494700 60 mg/day × 6 days, then 20 mg daily (high dose)
Trial: 24696507
Drug: PF‐04494700 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐04494700 15 mg/day × 6 days, then 5 mg daily (low dose)
Trial: 15297165
Drug: 4‐HPR (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐HPR (200 mg/day)
Trial: 11270943
Drug: Zafirlukast 40
RxNorm normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zafirlukast 40 mg twice daily
Trial: 11270943
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate 88 microg or salmeterol 42 microg
Trial: 9840560
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration of 0.5% bupivacaine before incision (Treatment group A)
Trial: 9840560
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo before skin incision and bupivacaine after laparoscopy (Treatment group B)
Trial: 9840560
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo before and after laparoscopy (Treatment group C)
Trial: 8206772
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three preparatory informational treatments
Trial: 2648645
Drug: Salbutamol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (200 micrograms by inhalation)
Trial: 10599554
Drug: Tibolone +
RxNorm normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone + fluoride (2.5 mg of tibolone + 26.4 mg of fluoride daily for 2 years)
Trial: 10599554
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + fluoride (placebo + 26.4 mg of fluoride daily for 2 years)
Trial: 2024543
Drug: Enalapril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (2.5 to 40 mg daily, mean 18.3 mg)
Trial: 6168856
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg digitoxin
Trial: 6168856
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg digitoxin
Trial: 6168856
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg digoxin
Trial: 24472398
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg OROS hydromorphone
Trial: 24472398
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg OROS hydromorphone
Trial: 24472398
Drug: 32 mg
RxNorm normalized name: caffeine 32 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 mg OROS hydromorphone
Trial: 24472398
Drug: 64 mg
RxNorm normalized name: sulfur 64 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 64 mg OROS hydromorphone
Trial: 24472398
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg naltrexone (concomitant with hydromorphone)
Trial: 20639832
Drug: Parenteral amino
RxNorm normalized name: parenteral amino acid 7 % comb no.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral amino acid (5%) supplementation
Trial: 20639832
Drug: Usual nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual nutritional management (10% intravenous dextrose and subsequent enteral feeding)
Trial: 17931979
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading dose then 75 mg daily)
Trial: 11909567
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum lipoprotein(a) (≥20 mg/dl) and high low-density lipoprotein (LDL) cholesterol (≥3.63 mmol/L [≥140 mg/dl])
Trial: 11909567
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum lipoprotein(a) (≥20 mg/dl) and high low-density lipoprotein (LDL) cholesterol (≥3.63 mmol/L [≥140 mg/dl]) combined with type 2 diabetes mellitus
Trial: 9817951
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (part of a multidisciplinary treatment package)
Trial: 9817951
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no cognitive behavioural therapy)
Trial: 2695151
Drug: Bromocriptine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (5 mg/day for three months)
Trial: 25200570
Drug: Dapagliflozin 5
RxNorm normalized name: dapagliflozin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 5 mg twice daily
Trial: 24054381
Drug: Polypropylene mesh
RxNorm normalized name: polypropylene (30000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypropylene mesh (PM) implant
Trial: 12360156
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) therapy
Trial: 12360156
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) therapy with GP IIb/IIIa receptor antagonists
Trial: 9469979
Drug: Radiosensitizer tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiosensitizer tablets Nimorazol given 1 1/2 hours before radiation, six fractions weekly for patients with squamous cell cancer in the supraglottic region, pharynx and oral cavity.
Trial: 9469979
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (specific details not provided).
Trial: 2665110
Drug: Arthritis Self‐management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthritis Self‐management Course (ASMC) + bi‐monthly arthritis newsletter
Trial: 141020
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy after subarachnoid injection of 0.25% procaine
Trial: 141020
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy after 1% procaine sensory and motor blockade
Trial: 27264267
Drug: Docetaxel plus
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel plus gemcitabine (DG) - docetaxel 30 mg/m2 plus gemcitabine 900 mg/m2 i.v. on days 1 and 8, every 3 weeks
Trial: 27264267
Drug: Gemcitabine (G)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (G) - gemcitabine 1200 mg/m2 i.v. on days 1 and 8, every 3 weeks
Trial: 27264267
Drug: Instrumental Activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instrumental Activities of Daily Living (IADL) score < 7
Trial: 27264267
Drug: Instrumental Activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instrumental Activities of Daily Living (IADL) score ≥ 7
Trial: 24483110
Drug: Jianbu Tongluo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jianbu Tongluo Xunzheng Liquid (JTXL), fumigated for 30 min once daily for 10 times (3 courses total)
Trial: 24483110
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of JTXL fumigation and Sodium Hyaluronate Injection (SHI), 3 mL each time, once per 6 days for 5 times
Trial: 24483110
Drug: Sodium Hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Hyaluronate Injection (SHI), 3 mL each time, once per 6 days for 5 times
Trial: 17853748
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (Jiaji EA plus laser needle-knife)
Trial: 8267111
Drug: Monosialoganglioside (GM1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monosialoganglioside (GM1) 100 mg/day i.m. for 6 weeks
Trial: 3115131
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg b.w. flecainide
Trial: 27056702
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) after RME (n=10)
Trial: 23616511
Drug: Psychosocial stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial stimulation (9 months of weekly play sessions at home)
Trial: 23616511
Drug: Iron treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron treatment (30 mg daily for 6 months)
Trial: 21039349
Drug: Perisciatic infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perisciatic infusion of ropivacaine 2 mg/ml at a rate of 5 ml/h
Trial: 21039349
Drug: Perisciatic infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perisciatic infusion of ropivacaine 2 mg/ml at a rate of 8 ml/h
Trial: 9048325
Drug: Goniometric measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goniometric measurement by inexperienced testers (physical therapy students)
Trial: 9048325
Drug: Visual estimation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visual estimation by inexperienced testers (physical therapy students)
Trial: 8393273
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose intensity regimens
Trial: 3554461
Drug: Clindamycin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin + Gentamycin (C + G)
Trial: 3554461
Drug: Metronidazole +
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole + Gentamycin (M + G)
Trial: 31755809
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (IVA) 2.0 mg
Trial: 31755809
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab (IVR) 0.5 mg